Efavirenz in the therapy of HIV infection Rakhmanina & van den Anker Efavirenz

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 1, 2010, Pages 95-103

  Rakhmanina, Natella Y ^a,b   Van Den Anker, John N ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; Efavirenz; HIV; Non nucleoside reverse transcriptase inhibitor; Pharmacogenetics

Indexed keywords

AMPRENAVIR; ATAZANAVIR; AZITHROMYCIN; BEPRIDIL; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ERGOT ALKALOID; ERGOT DERIVATIVE; FOSAMPRENAVIR; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TRIAZOLAM; UNINDEXED DRUG; VORICONAZOLE;

ABNORMAL DREAMING; ABNORMAL VISION; AGITATION; AMNESIA; ANOPHTHALMIA; ANOREXIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA MULTIFORME; FACE MALFORMATION; FOOD DRUG INTERACTION; GENE LOCATION; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GYNECOMASTIA; HALLUCINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIPODYSTROPHY; LIVER FAILURE; MALABSORPTION; MAXIMUM PLASMA CONCENTRATION; MENINGOMYELOCELE; MENTAL CONCENTRATION; MYALGIA; MYOPATHY; NAUSEA; NERVOUSNESS; NEURAL TUBE DEFECT; NEUROTOXICITY; PAIN; PHARMACOGENETICS; PSYCHOSIS; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDE; TERATOGENICITY; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS RESISTANCE; VOMITING; WILD TYPE;

ANTI-HIV AGENTS; BENZOXAZINES; CHEMISTRY, PHARMACEUTICAL; FOOD-DRUG INTERACTIONS; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 72949093735     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903483207     Document Type: Review

References (83)

1. UNAIDS. AIDS epidemic update: December 2007. Available from: Http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf. [Accessed 11 June, 2009]
2. Scaling up access to antiretroviral therapy to low- and midlde-income countries: Global and regional progress in 2008 WHO, UNAIDS, UNICEF. Availabe from: Http://wwwwhoint/hiv/mediacentre/ ias-2009pdf. [Accessed 31 August, 2009]
3. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008. p. 1-128. Available from: Http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL. pdf. [Accessed 27, March 2008]
4. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach RW, 2006. Available from: Http://www.who.int/hiv/ pub/guidelines/artadultguidelines.pdf. [Accessed 27 March, 2008]
5. UNAIDS. AIDS epidemic update : December 2007. Available from http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf. [Accessed 1 April, 2008.2007]
6. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial. JAMA 2006;296(7):769-781
7. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292(2):191-201
8. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341(25):1865-1873
9. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36(5):1011-1019
10. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358(20):2095-2106
11. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47(2):266-285
12. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004;363(9417):1253-1263
13. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23(9):1109-1118
14. Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials 2002;3(3):186-194
15. Ghosn J, Chaix ML, Delaugerre C. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev 2009;11(3):165-173
16. Scherrer AU, Hasse B, von Wyl V, et al. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: The Swiss HIV Cohort Study (SHCS). HIV Med 2009;10(10):647-656
17. FDA - Approval Letter. Available from: Http://www.fda.gov/cder/foi/ appletter/1998/20972ltr.pdf. [Accessed 12 July 2009]
18. Sustiva- Prescribing Information. Bristol-Myers Squibb Company. March 2009
19. ChemIDplus Advanced. Available from: Http://chem.sis.nlm.nih.gov/ chemidplus/ chemidheavy.jsp. Accessed July 12 2009
20. FDA Antiretrovirals Approved and Tentatively Approved in Association with the President's Emergency Plan Expedited Review Process. FDA, U.S. Department of Health and Human Services. Available from: Http://www.fda.gov/ InternationalPrograms/ FDABeyondOurBordersForeignOffices/ AsiaandAfrica/ ucm119231.htm. [Accessed 12 August 2009]
21. von Hentig N, Koenigs C, Elanjikal S, et al. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. Eur J Med Res 2006;11(9):377-380
22. Ren Y, Nuttall JJ, Egbers C, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr 2007;45(2):133-136
23. Wintergerst U, Hoffmann F, Jansson A, et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother 2008;61(6):1336-1339
24. Saitoh A, Fletcher CV, Brundage R, et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr 2007;45(3):280-285 (Pubitemid 47012374)
25. Fletcher CV, Brundage RC, Fenton T, et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther 2008;83(2):300-306
26. Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008;48(4):450-454
27. Teglas JP, Quartier P, Treluyer JM, et al. Tolerance of efavirenz in children. AIDS 2001;15(2):241-243
28. Starr SE, Fletcher CV, Spector SA, et al. Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002;21(7):659-663
29. ter Heine R, Scherpbier H, Crommentuyn K, et al. Population phramacokinetics in children. Current pediatric dosing guidelines may result in sub-therapeutic concentrations. Annual meeting of Amercian Society of Clinical Pharmaclogy and Therapeutics (ASCPT) Orlando, FL, 2008
30. Hirt D, Urien S, Olivier M, et al. Is the recommended dose of efavirenz optimal in young West African HIV-infected children? (ANRS 12103). Antimicrob Agents Chemother 2009;53(10):4407-4413
31. Mutlib AE, Chen H, Nemeth GA, et al. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: Species differences in the metabolism of efavirenz. Drug Metab Dispos 1999;27(11):1319-1333
32. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007;8(6):547-558
33. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306(1):287-300
34. Bumpus NN, Kent UM, Hollenberg PF. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther 2006;318(1):345-351
35. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics2009;19(4):300-309
36. Blank A, Hellstern V, Schuster D, et al. Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clin Infect Dis 2009;48(12):1787-1789
37. Lang T, Klein K, Richter T, et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: Demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004;311(1):34-43
38. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005;15(1):1-5
39. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004;319(4):1322-1326
40. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005;15(12):861-873
41. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group Study. AIDS 2004;18(18):2391-2400
42. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005;40(9):1358-1361
43. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006;42(3): 401-407
44. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008;61(4):914-918
45. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007;81(4):557-566
46. Kwara A, Lartey M, Sagoe KW, et al. CYP2B6 (c.516G->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009; 67(4):427-436
47. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007;45(9):1230-1237
48. Cabrera SE, Santos D, Valverde MP, et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother 2009;53(7):2791-2798
49. Arab-Alameddine M, Di Iulio J, Buclin T, et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009;85(5):485-494
50. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006;16(3):191-198
51. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008;64(4):357-365
52. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: An Adult AIDS Clinical Trials Group Study. J Infect Dis 2005;192(11):1931-1942
53. Gross R, Aplenc R, Tenhave T, et al. Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 2008;49(3):336-337
54. Leger P, Dillingham R, Beauharnais CA, et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis 2009;200(6):955-964
55. Mehlotra RK, Ziats MN, Bockarie MJ, et al. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006;62(4):267-275
56. Puthanakit T, Tanpaiboon P, Aurpibul L, et al. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. Antivir Ther 2009;14(3):315-320
57. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated November 3, 2008. Available from: Http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf. [Accessed 12 August 2009]
58. Poirier JM, Guiard-Schmid JB, Meynard JL, et al. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors. AIDS 2006;20(7):1087-1089
59. Sekar VJ, De Pauw M, Marien K, et al. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir Ther 2007;12(4):509-514 (Pubitemid 47041149)
60. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003;47(1):350-359
61. Sustiva- Prescribing Information. Bristol-Myers Squibb Company. September 2009
62. Matteelli A, Regazzi M, Villani P, et al. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 2007;5(3):349-353
63. Weiner M, Benator D, Peloquin CA, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis 2005;41(9):1343-1349
64. Damle B, LaBadie R, Crownover P, et al. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008;65(4):523-530
65. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001;51(3):213-217
66. Robertson SM, Penzak SR, Lane J, et al. A potentially significant interaction between efavirenz and phenytoin: A case report and review of the literature. Clin Infect Dis 2005;41(2):e15-18
67. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008;13(2):123-132
68. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40(3):468-474
69. Cassetti I, Madruga JV, Etze A, et al. The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naïve patients through seven years. 17th International AIDS Conference, Mexico City, Mexico; August 3-8, 2008. Abstract TUPE0057
70. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349(24):2293-2303
71. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350(18):1850-1861
72. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005;192(11):1921-1930
73. SaagMHJ, Goodrich J, et al. Reanalysis of the MERIT study with the enhanced TrofileTM assay. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA; 2008. Abstract H-1232
74. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46(2):125-133
75. Markowitz M NB-Y, Gotuzzo E, et al. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naI€ve HIV-1-infected patients: 96-week data. In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, Mexico, 2008. Abstract TUAB0102
76. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15(1):71-75 (Pubitemid 32055781)
77. Saitoh A, Hull AD, Franklin P, et al. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005;25(8):555-556
78. Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep 2007;4(3):135-140
79. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Updated February 23, 2009. Available from: Http://aidsinfo.nih.gov/ contentfiles/PediatricGuidelines.pdf. [Accessed June 27 2009]
80. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004;1(1):e19
81. McComsey G, Bhumbra N, Ma JF, et al. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: Results of the First Pediatric Switch Study. Pediatrics 2003;111(3):e275-81
82. Scherpbier HJ, Bekker V, Pajkrt D, et al. Once-daily highly active antiretroviral therapy for HIV-infected children: Safety and efficacy of an efavirenz-containing regimen. Pediatrics 2007;119(3):e705-15
83. Rathore M, McKinney R, Hu C, et al. PACTG protocol 1021: A phase I/II study of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA; 2008. Abstract 581